In Vitro Synergistic Antimicrobial Effect of Imipenem and Colistin Against an Isolate of Multidrug-resistant Enterobacter cloacae

Journal of Microbiology, Immunology and Infection

Volumn 43, Issue 4, 2010, Pages 317-322

  Lin, Kuan Hung ^a   Chuang, Yin Ching ^a   Lee, Shih Hui ^a   Yu, Wen Liang ^a,b  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Colistin; Enterobacter cloacae; Imipenem; Minimal inhibitory concentrations; Time kill study

Indexed keywords

AMIKACIN; AMPICILLIN; BACTERIAL ENZYME; BETA LACTAMASE CTX M; BETA LACTAMASE SHV; BETA LACTAMASE TEM 1; CEFAZOLIN; CEFEPIME; CEFPIROME; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; COLISTIN; ERTAPENEM; FLOMOXEF; GENTAMICIN; IMIPENEM; LOMEFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; ASPIRATION PNEUMONIA; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTEROBACTER CLOACAE; FATALITY; FEMALE; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; SPUTUM CULTURE; THORAX RADIOGRAPHY; VENTILATOR ASSOCIATED PNEUMONIA; DRUG EFFECTS; GRAM POSITIVE INFECTION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; MIDDLE AGED; SPUTUM; TIME;

ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; ENTEROBACTER CLOACAE; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MIDDLE AGED; PNEUMONIA, BACTERIAL; SPUTUM; TIME FACTORS;

EID: 77955331009     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1684-1182(10)60049-7     Document Type: Article

References (32)

1. Clinical and Laboratory Standards Institute (formerly NCCLS) Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A8 2006, Clinical and Laboratory Standards Institute, Wayne, PA.
2. Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ Antimicrobial susceptibility among organisms from the Asia/ Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 2007, 60:1018-1029.
3. Clark NM, Patterson J, Lynch JP Antimicrobial resistance among gram-negative organisms in the intensive care unit. Curr Opin Crit Care 2003, 9:413-423.
4. Hoffmann H, Sturenburg E, Heesemann J, Roggenkamp A Prevalence of extended-spectrum beta-lactamases in isolates of the Enterobacter cloacae complex from German hospitals. Clin Microbiol Infect 2006, 12:322-330.
5. Tresoldi AT, Padoveze MC, Trabasso P, Veiga JF, Marba ST, von Nowakonski A, et al. Enterobacter cloacae sepsis outbreak in a newborn unit caused by contaminated total parenteral nutrition solution. Am J Infect Control 2000, 28:258-261.
6. van Dijk Y, Bik EM, Hochstenbach-Vernooij S, van der Vlist GJ, Savelkoul PH, Kaan JA, et al. Management of an outbreak of Enterobacter cloacae in a neonatal unit using simple preventive measures. J Hosp Infect 2002, 51:21-26.
7. Sanders WE, Sanders CC Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin Microbiol Rev 1997, 10:220-241.
8. Wendt C, Lin D, von Baum H Risk factors for colonization with third-generation cephalosporin-resistant enterobacteriaceae. Infection 2005, 33:327-332.
9. Ye Y, Li JB, Ye DQ, Jiang ZJ Enterobacter bacteremia: Clinical features, risk factors for multi-resistance and mortality in a Chinese University Hospital. Infection 2006, 34:252-257.
10. Paterson DL Resistance in gram-negative bacteria: enterobacte-riaceae. Am J Med 2006, 119:S20-S28.
11. Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 2001, 45:2628-2630.
12. Liu CP, Wang NY, Lee CM, Weng LC, Tseng HK, Liu CW, et al. Nosocomial and community-acquired Enterobacter cloacae bloodstream infection: risk factors for and prevalence of SHV-12 in multi-resistant isolates in a medical centre. J Hosp Infect 2004, 58:63-77.
13. Clissold SP, Todd PA, Campoli-Richards DM Imipenem/ Cilastatin: a review of its anti-bacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1987, 33:183-241.
14. Koyama Y, Kurosawa A, Tsuchiya A, Takakuta K A new antibiotic, colistin, produced by spore-forming soil bacteria. J Antibiot Tokyo 1950, 3:457.
15. Price DJE, Graham DI Effect of large doses of colistin sulphomethate on renal function. BMJ 1970, 4:525-527.
16. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE Adverse effects of sodium colistin methate: manifestations and specific reaction rates during 317 courses of therapy. Ann Inter Med 1970, 72:857-868.
17. Littlewood JM, Koch C, Lambert PA, Hoiby N, Elborn JS, Conway SP, et al. A ten-year review of colimycin. Resp Med 2000, 94:632-640.
18. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K Evaluation of colistin as an agent against multi-resistant Gram negative bacteria. Int J Antimicrob Agents 2005, 25:11-25.
19. Catchpole CR, Andrews JM, Brenwald N, Wise R A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 1997, 39:255-260.
20. Pitt TL, Sparrow M, Warner M, Stefanidou M Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 2003, 58:794-796.
21. th ed. M7-A7 2006, Clinical Laboratory Standards Institute, Villanova, Pa.
22. Chuang YC, Liu JW, Ko WC, Lin KY, Wu JJ, Huang KY In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus. Antimicrob Agents Chemother 1997, 41:2214-2217.
23. Wu LT, Tsou MF, Wu HJ, Chen HE, Chuang YC, Yu WL Survey of CTX-M-3 extended-spectrum ß-lactamase (ESBL) among cefotaxime-resistant Serratia marcescens at a medical center in middle Taiwan. Diagn Microbiol Infect Dis 2004, 49:125-129.
24. Yu WL, Cheng KC, Chi CH, Chen HE, Chuang YC, Wu LT Characterization and molecular epidemiology of extended-spectrum ß-lactamase-producing Enterobacter cloacae isolated from a district teaching hospital in Taiwan. Clin Microbiol Infect 2006, 12:579-582.
25. Su PA, Wu LT, Cheng KC, Ko WC, Chuang YC, Yu WL Screening extended-spectrum ß-lactamase production in Enterobacter cloacae and Serratia marcescens by using antibiogram-based methods. J Microbiol Immunol Infect 2010, 43:26-34.
26. Bush K, Jacoby GA, Medeiros AA A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995, 39:1211-1233.
27. Livermore DM Beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995, 8:557-584.
28. Jiang X, Ni Y, Jiang Y, Yuan F, Han L, Li M, et al. Outbreak of infection caused by Enterobacter cloacae producing the novel VEB-3 beta-lactamase in China. J Clin Microbiol 2005, 43:826-831.
29. Walsh TR, Toleman MA, Poirel L, Nordman P Metallo-beta-lactamases: the quiet before the storm?. Clin Microbiol Rev 2005, 18:306-325.
30. Tascini C, Urbani L, Biancofiore G, Rossolini GM, Leonildi A, Gemignani G, et al. Colistin in combination with rifampin and imipenem for treating a blaVIM-1 metallo-beta-lactamase-producing Enterobacter cloacae disseminated infection in a liver transplant patient. Minerva Anestesiol 2008, 74:47-49.
31. Yu WL, Chuang YC, Walther-Rasmussen J Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control. J Microbiol Immunol Infect 2006, 39:264-277.
32. Ku YH, Chuang YC, Yu WL In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae. J Microbiol Immunol Infect 2008, 41:332-336.